Simply put… Despite the clinical focus on increasing fatty acid oxidation to clear surplus fat stores in obese and diabetic individuals, new research suggests that increasing fatty acid metabolism does more harm than good. This article provides insight into the complex balance of glucose and fatty acid metabolism, and why blocking fatty acid metabolism may be a more appropriate therapeutic option for obese and type 2 diabetic patients. The link between obesity and diabetes is unquestionable, so the global rise in obesity and type 2 diabetes (T2D) rates is no surprise. A 2014 report from Statistics Canada suggests that more
PEA (N-palmitoylethanolamide): An endogenous fatty acid amide synthesized and metabolized by cells that binds to cell receptors. It influences a multitude of physiological functions and has potent anti-inflammatory and pain-relieving properties.
Endocannabinoid System: A lipid communication network that has critical physiological functions and serves a vital purpose for our health and well-being through signaling processes, homeostasis and hormone regulation.
Lipids and the ECS
In 1929, scientists George Oswald Burr and his wife, Mildred Burr, discovered that omega 6 fatty acids were essential for health. This kicked off science’s interest into lipids, and by the 1960s a new age of lipid research had begun. Edward Dennis of University of California at San Diego wrote:
“Lipids are in many ways the most important of the biomolecules because they are the ultimate controllers and regulators of our bodily processes; they are key to signaling events in cells. Further, imbalances in lipids are implicated in many illnesses, such as heart disease, stroke, arthritis, diabetes and Alzheimer disease. If we are going to solve these diseases, we must know what the lipids are and what they do.”
The endocannabinoid system (ECS) is a lipid communication network with important physiological functions in all animal life. The complex biochemical array of pathways involved in the synthesis, release, transport, and degradation of endocannabinoids by the body is also known as the endocannabinoidome. This lipid signaling network is a key modulator of physiological functions in many of the other networks and signaling systems including; the nervous system, the endocrine network, the immune system, the gastrointestinal tract, and the reproductive system, as well as others.
Endocannabinoids, the products of the ECS, are directly released from membranes, which distinguishes them from other transmitter molecules, such as dopamine or hormones. Moreover, unlike the neurotransmitters or hormones, which are synthesized in one place but act globally in the body, the endocannabinoids are synthesized locally and act locally.
PEA – The Rising Star of the ECS
Classical endocannabinoids include, anandamide (also termed AEA) and 2-acyl glycerol (2-AG). But other endocannabinoids were later discovered, and one in particular has been studied in considerable detail, N-palmitoylethanolamide or PEA. The origins of PEA started in 1939 when clinician and researcher Coburn was looking into how to prevent the incidence of rheumatic fever in poor children living in New York. He stumbled upon egg yolk as a key ingredient that prevented and/or reduced rheumatic fever. In 1957 scientists at Merck Sharp and Dome identified PEA as the molecule that provided this protection against streptococcal infection and rheumatic fever.
However, it wasn’t until 1993 that the mechanism of action of PEA was determined through the work of Rita Levi-Montalcini an Italian scientist who back in 1954 had discovered the nerve growth factor (NGF).
Levi-Montalcini’s discovery was that NGF activated specific immune cells called mast cells that further caused inflammation and allergic reactions. Almost forty years later, she discovered how a naturally produced fatty acid amide called PEA stopped the activation of mast cells, thereby preventing inflammation and allergies. Furthermore, Levi-Montalcini discovered that PEA was produced locally by cells under threat from noxious and injurious external triggers, like UV-A, various toxins, allergens, infectious agents as well as other inflammatory agents. The local production of PEA thereby reduced their threat. PEA was not only produced locally but also acted locally. It seemed like PEA was called into action whenever there was demand, when the body needed protection not only against outside triggers but also when the body was under threat from within, for example against ageing or whenever the immune system was overactive as in various autoimmune disorders, which occurs when the body stops recognizing friend from foe, and starts acting against itself. Mast cells seem to be key components of the inflammatory response.
Levi-Montalcini succinctly pointed out the interaction between PEA and the mast cell:
“…Unregulated mast-cell activation constitutes a considerable risk to the health of the organism, and it is not unreasonable to expect that nature should have devised a means for the host to defend itself against such damage. It has recently been proposed that saturated N-acylethanolamine like palmitoylethanolamide (PEA), which accumulate in tissues following injury and which down modulate mast cell activation, exert a local, and anti-injury function via mast cells. Palmitoylethanolamide is orally active in reducing tissue inflammation and mast cells.”
Once the mechanism of action of PEA was identified, there was a flurry of research on PEA, and new and interesting health benefits were soon discovered. As early as 1980, it was learned that PEA had a tendency to accumulate in the damaged heart muscle due to ischemia or deprivation of oxygen, and this might be of physiological importance because of its anti-inflammatory properties. Researcher Denis Epps suggested that these fatty molecules played a protective role, and that their presence, “may signify a response of myocardial tissue to injury directed at minimizing damage and promoting survival”.
Recent studies have confirmed what Epps and his colleagues postulated. It has been shown in various animal disease models, and human tissue analysis that PEA protects various tissues, including the colon, kidney and particularly the nervous tissue. It shows potential benefits in spinal cord injury as well as other conditions like shock, stroke, MS and Alzheimer’s.
Currently there are number of animal and human studies on the application of PEA in the following conditions:
- Benign prostatic hyperplasia (BPH)
- Burning mouth syndrome
- Inflammatory bowel disease and syndrome (IBD/IBS)
- Transient brain injury
- Pain originating from various types
- Coronary heart disease
- Chronic kidney disease
- Atopic dermatitis and eczema
- Cannabis dependence
- Infectious diseases
In conclusion, PEA is an endogenously, and locally produced anti-injury molecule, the sole function of which is to offer immediate protection through down modulating disease processes and acting against noxious stimuli in various systems of the body. The medical potential of this fascinating and undervalued molecule that comes to the body’s rescue when the need arises is worthy of wider attention in the context of ongoing research into the endocannabinoid system.
- Kuehl FA, Jacob TA, Ganley OH, Ormond RE, Meisinger MAP (1957) The identification of N-2-hydroxyethyl-palmitamide as a natural occurring anti-inflammatory agent. J Am Chem Soc 79: 5577-5578.
- Epps DE, Natarajan V, Schmid PC, Schmid HO (1980) Accumulation of N-acylethanolamine glycerophospholipids in infarcted myocardium. Biochim Biophys Acta 618: 420-430.
- Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, et al. (2011) Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun 25: 1099-1112.
- Keppel Hesselink JM, Hekker TA (2012) Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res 5: 437-442.
- Petrosino S, Iuvone T, Di Marzo V (2010) N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie 92: 724-727.
- Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, et al. (2012) Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med 13: 1121-1130.
- Keppel Hesselink, J (2013) Professor Rita Levi-Montalcini on Nerve Growth Factor, Mast Cells and Palmitoylethanolamide, an Endogenous Anti-Inflammatory and Analgesic . Compound Pain Relief 2013, 2:1-5